|Daily Range||$8.94 - $9.50|
|52-Week Range||$3.43 - $26.00|
|Dividend (Yield)||$0.00 (0.0%)|
|Average Daily Volume||141,235|
|Current FY EPS||-$0.69|
Prosensa Holding B.V. (RNA) Description
Prosensa Holding B.V. Website: http://www.prosensa.eu/
News & Commentary
These health-care stocks experienced a horrendous week -- with each plunging more than 20%.
Should You Buy Prosensa Holding (RNA) Ahead of Earnings? - Tale of the Tape
Sarepta Therapeutics fell on its 144-week data, but the approvability -- based on trials run by PTC Therapeutics and Prosensa -- is likely to be based on 48-week data.
Sarepta has updated data from eteplirsen's trial in Duchenne's muscular dystrophy, potentially positioning it to compete against Prosensa's drisapersen and PTC Therapeutics Translarna.
Sarepta Therapeutics is down over 20% today on disappointing clinical trial news. Here's what you need to know.